Nrf2-keap1 pathway promotes cell proliferation and diminishes ferroptosis

Oncogenesis

Volumn 6, Issue 8, 2017, Pages

  Fan, Z ^a,b   Wirth, A K ^a,c   Chen, D ^a,d   Wruck, C J ^e   Rauh, M ^f   Buchfelder, M ^a   Savaskan, N ^a,g  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b ETH ZURICH   (Switzerland)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g BiMECON Ent   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85034628793     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2017.65     Document Type: Article

References (49)

1. O'Connell MA, Hayes JD. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans 2015; 43: 687–689.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
3. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 1994; 91: 9926–9930.
4. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58: 262–270.
5. Chan K, Lu R, Chang J. C, Kan Y. W. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and devel-opment. Proc Natl Acad Sci USA 1996; 93: 13943–13948.
6. Lu K, Alcivar AL, Ma J, Foo TK, Zywea S, Mahdi A et al. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction. Cancer Res 2017; 77: 2881–2892.
7. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38: 769–789.
8. Gañán-Gómez I, Wei Y, Yang H, Boyano-Adáneza M. C, García-Manero G. Onco-genic functions of the transcription factor Nrf2. Free Radical Biol Med 2013; 65: 750–764.
9. Ikeda H, Nishi S, Sakai M. Transcription factor Nrf2/MafK regulates rat placental glutathione S-transferase gene during hepatocarcinogenesis. Biochem J 2004; 380: 515–521.
10. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010; 220: 446–451.
11. Shen H, Zhou S, Wang J. The paradoxical role of Nrf2 in tumor biology. Crit Rev Eukaryot Gene Expr 2013; 23: 37–47.
12. Habib E, Linher-Melville K, Lin HX, Singh G. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress. Redox Biol 2015; 5: 33–42.
13. Lewerenz J, Albrecht P, Tien ML, Henke N, Karumbayaram S, Kornblum HI et al. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J Neurochem 2009; 111: 332–343.
14. Ye P, Mimura J, Okada T, Sato H, Liu T, Maruyama A et al. Nrf2-and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol 2014; 34: 3421–3434.
15. Savaskan N. E. Eyupoglu IY xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. Anna Anat 2010; 192: 309–313.
16. Savaskan N. E, Fan Z, Broggini T, Buchfelder M, Eyüpoglu I. Y. Neurodegeneration in the brain tumor microenvironment: glutamate in the limelight. Curr Neuro-pharmacol 2015; 13: 258–265.
17. Sehm T, Fan Z, Ghoochani A, Rauh M, Engelhorn T, Minakaki G et al. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget 2016; 7: 36021–36033.
18. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O et al. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegen-eration and alleviates brain edema. Nat Med 2008; 14: 629–632.
19. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med 2011; 17: 1269–1274.
20. Comen E. A. Tracking the seed and tending the soil: evolving concepts in meta-static breast cancer. Discov Med 2012; 14: 97–104.
21. Shiwarski D. J, Shao C, Bill A, Kim J, Xiao D, Bertrand C. A et al. To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clinical Cancer Res 2014; 20: 4673–4688.
22. Roh J. L, Kim E. H, Jang H, Shin D. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Free Radical Biol Mede 2017; 104: 1–9.
23. Yang W. S, Stockwell B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008; 15: 234–245.
24. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060–1072.
25. Chen D, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan NE. The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas. Oncotarget (e-pub ahead of print 9 May 2017; doi:10.18632/oncotarget.17737).
26. Ji XJ, Chen SH, Zhu L, Pan H, Zhou Y, Li W et al. Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model. Oncol Rep 2013; 30: 157–164.
27. Chen J, Yu Y, Ji T, Ma R, Chen M, Li G et al. Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma. Cancer Med 2016; 5: 2678–2687.
28. Tong YH, Zhang B, Yan YY, Fan Y, Yu JW, Kong SS et al. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer. Oncotarget 2017; 8: 45750–45758.
29. Was H, Cichon T, Smolarczyk R, Rudnicka D, Stopa M, Chevalier Cet al. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol 2006; 169: 2181–2198.
30. Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother Pharmacol 2012; 69: 485–494.
31. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009; 15: 3423–3432.
32. Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 2011; 10: 37.
33. Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M et al. Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling. Oncogene 2008; 27: 5821–5832.
34. Lee D. F, Kuo H. P, Liu M, Chou C. K, Xia W, Du Y et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009; 36: 131–140.
35. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 2014; 39: 199–218.
36. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic repro-gramming. Cancer Cell 2012; 22: 66–79.
37. Pan H, Wang H, Zhu L, Wang X, Cong Z, Sun K et al. The involvement of Nrf2-ARE pathway in regulation of apoptosis in human glioblastoma cell U251. Neurol Res 2013; 35: 71–78.
38. Zhou Y, Wang H. D, Zhu L, Cong Z. X, Li N, Ji X. J et al. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Oncol Rep 2013; 29: 394–400.
39. Zhou S, Ye W, Zhang M, Liang J. The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action. Crit Rev Eukaryot Gene Expr 2012; 22: 149–160.
40. Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem 2002; 277: 44765–44771.
41. Tebay L. E, Robertson H, Durant S. T, Vitale S. R, Penning T. M, Dinkova-Kostova A. T et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radical Biol Med 2015; 88(Part B): 108–146.
42. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135: 1358–1368 1368 e1351-1354.
43. Ganan-Gomez I, Wei Y, Yang H, Boyano-Adanez MC, Garcia-Manero G. Oncogenic functions of the transcription factor Nrf2. Free Radical Biol Med 2013; 65: 750–764.
44. Ren J. H, He W. S, Nong L, Zhu Q. Y, Hu K, Zhang R. G et al. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 2010; 25: 75–80.
45. Fan Z, Bittermann-Rummel P, Yakubov E, Chen D, Broggini T, Sehm T et al. PRG3 induces Ras-dependent oncogenic cooperation in gliomas. Oncotarget 2016; 7: 26692–26708.
46. Broggini T, Nitsch R, Savaskan NE. Plasticity-related gene 5 (PRG5) induces filo-podia and neurite growth and impedes lysophosphatidic acid-and nogo-A-mediated axonal retraction. Mol Biol Cell 2010; 21: 521–537.
47. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004; 32: 936–948.
48. Sander E. E, ten Klooster J. P, van Delft S, van der Kammen R. A, Collard J. G. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. JCellBiol1999; 147: 1009–1022.
49. Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA et al. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest 2007; 117: 2962–2973.